Corrigendum: IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation (International Immunology (2014) 26:7(357-367) DOI: 10.1093/intimm/dxt073);IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation

International Immunology

Volumn 26, Issue 7, 2014, Pages 357-367

  Metz, Richard ^a   Smith, Courtney ^b   DuHadaway, James B ^b   Chandler, Phillip ^c   Baban, Babak ^c   Merlo, Lauren M F ^b   Pigott, Elizabeth ^b   Keough, Martin P ^b   Rust, Sonja ^a   Mellor, Andrew L ^c   Mandik Nayak, Laura ^b,d   Muller, Alexander J ^b,e   Prendergast, George C ^b,d,e  

^a New Link Genetics Corporation   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c AUGUSTA UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adaptive immunity; Contact hypersensitivity; Inflammation; Tolerance

Indexed keywords

ENZYME; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HAPTEN; IDO1 ENZYME; IDO2 ENZYME; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; KYNURENINE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 4-O-METHYL-12-O-TETRADECANOYLPHORBOL 13-ACETATE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; CARCINOGEN; CYTOKINE; IDO1 PROTEIN, MOUSE; IDO2 PROTEIN, MOUSE; INDOLEAMINE 2,3 DIOXYGENASE; PHORBOL 13 ACETATE 12 MYRISTATE;

ADAPTIVE IMMUNITY; AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER SUSCEPTIBILITY; CATABOLISM; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EAR EDEMA; EMBRYO DEVELOPMENT; EPISTASIS; EXON; GENE INTERACTION; HEMATOPOIETIC CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; LANGERHANS CELL; LYMPH NODE; MOSAICISM; MOUSE; NONHUMAN; NULL ALLELE; PAPILLOMA; PERITONEUM; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA SPLICING; SEQUENCE ANALYSIS; SKIN CANCER; SKIN CARCINOGENESIS; SPLEEN; T LYMPHOCYTE; THYMUS; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DEFICIENCY; DENDRITIC CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; MIXED LYMPHOCYTE CULTURE; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; TH1 TH2 BALANCE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CYTOKINES; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; KYNURENINE; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MICE; MICE, KNOCKOUT; PAPILLOMA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TETRADECANOYLPHORBOL ACETATE; TH1-TH2 BALANCE;

EID: 84896516675     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxz003     Document Type: Erratum

References (45)

1. Ball, H. J., Sanchez-Perez, A., Weiser, S. et al. 2007. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396:203.
2. Metz, R., Duhadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J. and Prendergast, G. C. 2007. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 67:7082.
3. Opitz, C. A., Litzenburger, U. M., Sahm, F. et al. 2011. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197.
4. Prendergast, G. C., Chang, M. Y., Mandik-Nayak, L., Metz, R. and Muller, A. J. 2011. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr. Med. Chem. 18:2257.
5. Nowak, E. C., de Vries, V. C., Wasiuk, A. et al. 2012. Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J. Exp. Med. 209:2127.
6. Witkiewicz, A. K., Costantino, C. L., Metz, R. et al. 2009. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J. Am. Coll. Surg. 208:781; discussion 787.
7. Yuasa, H. J., Ball, H. J., Ho, Y. F. et al. 2009. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 153:137.
8. Munn, D. H., Zhou, M., Attwood, J. T. et al. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191.
9. Mellor, A. L., Sivakumar, J., Chandler, P. et al. 2001. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol. 2:64.
10. Yuasa, H. J., Ball, H. J., Austin, C. J. and Hunt, N. H. 2010. 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 157:10.
11. Qian, F., Liao, J., Villella, J. et al. 2012. Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol. Immunother. 61:2013.
12. Fukunaga, M., Yamamoto, Y., Kawasoe, M. et al. 2012. Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis. J. Histochem. Cytochem. 60:854.
13. Liu, X., Newton, R. C., Friedman, S. M. and Scherle, P. A. 2009. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr. Cancer Drug Targets 9:938.
14. Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E. and Prendergast, G. C. 2005. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11:312.
15. Hou, D. Y., Muller, A. J., Sharma, M. D. et al. 2007. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67:792.
16. Muller, A. J., DuHadaway, J. B., Chang, M. Y. et al. 2010. Nonhematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol. Immunother. 59:1655.
17. Smith, C., Chang, M. Y., Parker, K. H. et al. 2012. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2:722.
18. Metz, R., Rust, S., Duhadaway, J. B. et al. 2012. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 1:1460.
19. Munn, D. H., Sharma, M. D., Baban, B. et al. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22:633.
20. Yuasa, H. J. and Ball, H. J. 2013. Indoleamine 2,3-dioxygenases with very low catalytic activity are well conserved across kingdoms: IDOs of Basidiomycota. Fungal Genet. Biol. 56:98.
21. Muller, A. J., Sharma, M. D., Chandler, P. R. et al. 2008. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl Acad. Sci. USA 105:17073.
22. Muller, A. J., DuHadaway, J. B., Jaller, D., Curtis, P., Metz, R. and Prendergast, G. C. 2010. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res. 70:1845.
23. Pigott, E. and Mandik-Nayak, L. 2012. Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice. Arthritis Rheum. 64:2169.
24. Mellor, A. L., Baban, B., Chandler, P. R., Manlapat, A., Kahler, D. J. and Munn, D. H. 2005. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 175:5601.
25. Sharma, M. D., Baban, B., Chandler, P. et al. 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117:2570.
26. Mellor, A. L. and Munn, D. H. 2008. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol. 8:74.
27. Baban, B., Chandler, P. R., Sharma, M. D. et al. 2009. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183:2475.
28. Sharma, M. D., Hou, D. Y., Liu, Y. et al. 2009. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113:6102.
29. Mellor, A. L. and Munn, D. H. 2011. Physiologic control of the functional status of Foxp3+ regulatory T cells. J. Immunol. 186:4535.
30. Xu, J., Grewal, I. S., Geba, G. P. and Flavell, R. A. 1996. Impaired primary T cell responses in L-selectin-deficient mice. J. Exp. Med. 183:589.
31. Asherson, G. L. and Ptak, W. 1968. Contact and delayed hypersensitivity in the mouse. I. Active sensitization and passive transfer. Immunology 15:405.
32. Kunstfeld, R., Hirakawa, S., Hong, Y. K. et al. 2004. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104:1048.
33. Baban, B., Chandler, P., McCool, D., Marshall, B., Munn, D. H. and Mellor, A. L. 2004. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61:67.
34. Huang, L., Baban, B., Johnson, B. A., 3rd and Mellor, A. L. 2010. Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int. Rev. Immunol. 29:133.
35. Prendergast, G. C., Metz, R. and Muller, A. J. 2010. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am. J. Pathol. 176:2082.
36. Hope, J. C., Campbell, F. and Hopkins, S. J. 2000. Deficiency of IL-2 or IL-6 reduces lymphocyte proliferation, but only IL-6 deficiency decreases the contact hypersensitivity response. Eur. J. Immunol. 30:197.
37. Gillessen, S., Mach, N., Small, C., Mihm, M. and Dranoff, G. 2001. Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivity. Blood 97:922.
38. Gorbachev, A. V. and Fairchild, R. L. 2001. Induction and regulation of T-cell priming for contact hypersensitivity. Crit. Rev. Immunol. 21:451.
39. Reeve, V. E., Bosnic, M. and Nishimura, N. 1999. Interferongamma is involved in photoimmunoprotection by UVA (320-400 nm) radiation in mice. J. Invest. Dermatol. 112:945.
40. Pasparakis, M., Alexopoulou, L., Episkopou, V. and Kollias, G. 1996. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184:1397.
41. Jux, B., Kadow, S. and Esser, C. 2009. Langerhans cell maturation and contact hypersensitivity are impaired in aryl hydrocarbon receptor-null mice. J. Immunol. 182:6709.
42. Steinman, R. M., Hawiger, D. and Nussenzweig, M. C. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685.
43. Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J. and Bradfield, C. A. 2010. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185:3190.
44. Nguyen, N. T., Kimura, A., Nakahama, T. et al. 2010. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl Acad. Sci. USA 107:19961.
45. Vogel, C. F., Goth, S. R., Dong, B., Pessah, I. N. and Matsumura, F. 2008. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem. Biophys. Res. Commun. 375:331.